AI-generated analysis. Always verify with the original filing.
AN2 Therapeutics, Inc. entered into a Securities Purchase Agreement on March 8, 2026, involving the offer and sale of unregistered securities including Pre-Funded Warrants and underlying shares of Common Stock. Exhibits include the Form of Pre-Funded Warrant and the Securities Purchase Agreement.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 8, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into a Securities Pur
. The offer and sale of the Securities and the shares of Common Stock underlying the Pre-Funded Warrants have not been registered under the Securities Act of 19
, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabili
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1 Securities Purchase Agreement, dated March 8, 2026
Material Agreement